Clinical Trials Browser

Breast Neoplasms

NCT07085767 2026-03-16

OPERA-02

Phase 3 Recruiting

1,000 enrolled

Breast

Breast Neoplasms

NCT07237256 2026-03-16

NoLEEta

Phase 3 Recruiting

3,902 enrolled

Breast

Breast Neoplasms

NCT06065748 2026-03-09

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

1,050 enrolled

Breast

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT07174336 2026-03-06

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

920 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03701334 2026-03-03

NATALEE

Phase 3 Active not recruiting

5,101 enrolled 2 FDA

Breast

Breast Neoplasms

NCT05827081 2026-03-02

Adjuvant WIDER

Phase 3 Recruiting

1,400 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT06760637 2026-03-02

FourLight-3

Phase 3 Recruiting

1,020 enrolled

Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06585969 2026-02-12

DISCORDANT

Phase 3 Withdrawn

Breast

Breast Neoplasms

NCT07400523 2026-02-10

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Phase 3 Not yet recruiting

446 enrolled

Breast

Breast Neoplasms

NCT04964934 2026-01-16

SERENA-6

Phase 3 Active not recruiting

315 enrolled

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT04055493 2025-08-26

ADAPTcycle

Phase 3 Active not recruiting

1,684 enrolled

Breast

Breast Neoplasms

NCT05207709 2025-04-29

HARMONIA

Phase 3 Active not recruiting

456 enrolled

Breast

Breast Neoplasms

Clinical Trials

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

OPERA-02

NoLEEta

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

NATALEE

Adjuvant WIDER

FourLight-3

DISCORDANT

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

SERENA-6

ADAPTcycle

HARMONIA